Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.